降糖药物心血管结局试验更新
近期发表的三项降糖药物心血管结局研究(利格列汀、阿必鲁肽、达格列净)补充了同类药物先前十二项研究。CARMELINA 证实 DPP4 抑制剂总体心血管安全性,但三项 DPP4 抑制剂 CVOT 提示胰腺炎风险信号;Harmony Outcome 显示阿必鲁肽在已有心血管疾病者中显著降低 MACE;DECLARE-TIMI 58 表明达格列净对心衰和肾功能下降有强保护,但 MACE 结果与恩格列净、卡格列净不一致。建议所有合并心血管疾病的 2 型糖尿病患者使用 GLP-1 受体激动剂,心衰高风险或 eGFR 进行性下降者使用 SGLT2 抑制剂,DPP4 抑制剂为安全选择。
要点
- 合并心血管疾病的 2 型糖尿病患者应使用 GLP-1 受体激动剂。
- 心衰高风险或 eGFR 进行性下降者应使用 SGLT2 抑制剂。
- DPP4 抑制剂总体心血管安全,但需警惕胰腺炎风险信号。
核心结论
- 建议所有合并心血管疾病的 2 型糖尿病患者使用 GLP-1 受体激动剂。
- 心衰高风险或 eGFR 进行性下降者应使用 SGLT2 抑制剂。
- DPP4 抑制剂是降糖阶梯算法中的安全选择。
研究设计与样本
- 综述近期发表的三项降糖药物心血管结局研究及先前十二项同类研究。
- CARMELINA 研究纳入肾病及既往心血管事件人群评估利格列汀。
- Harmony Outcome 研究评估阿必鲁肽,DECLARE-TIMI 58 研究评估达格列净。
主要发现
- CARMELINA 证实 DPP4 抑制剂总体心血管安全性,利格列汀无心力衰竭风险。
- 三项 DPP4 抑制剂 CVOT 提示胰腺炎风险信号。
- 阿必鲁肽在已有心血管疾病者中显著降低 MACE 复合终点,与利拉鲁肽和司美格鲁肽一致。
- 达格列净对心衰有强保护,对肾功能下降有强保护,风险估计与恩格列净和卡格列净相似。
- 达格列净的 MACE 结果与恩格列净和卡格列净研究不一致,未显示令人信服的优效性。
关键数值与推荐
- GLP-1 受体激动剂的阳性效应可在 12 个月之前检测到并持续整个研究期间。
- 阿必鲁肽研究未发现新的安全性问题,该类药物的胰腺炎或胰腺癌信号已明确缺乏。
- 达格列净对心衰的保护在已有心血管疾病者中明确,在无既往心血管疾病者中可能也存在。
临床怎么用
- 合并心血管疾病的 2 型糖尿病患者应选用 GLP-1 受体激动剂。
- 心衰高风险或 eGFR 进行性下降者应选用 SGLT2 抑制剂。
- DPP4 抑制剂可用于降糖阶梯治疗,但需关注胰腺炎风险。
- 足部血管问题或既往截肢者及胰岛素使用者使用 SGLT2 抑制剂需谨慎。
局限性
- 达格列净的 MACE 结果与恩格列净和卡格列净研究不一致,跨类药物和长期优效性不令人信服。
- 阿必鲁肽研究持续时间短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Three further cardiovascular (CV) outcome studies of glucose-lowering drugs (linagliptin, albiglutide and dapagliflozin) have recently been published, adding to the twelve earlier within-class studies. The linagliptin study (CARMELINA) recruited people with renal disease as well as prior CV events and confirms the overall CV safety (and other safety) of the dipeptidylpeptidase-4 (DPP4) inhibitors, with no heart failure risk associated with this agent. However, taken together with the findings from two previous studies of DPP4 inhibitors (sitagliptin and saxagliptin), the three DPP4 inhibitor CV outcome trials (CVOTs) have highlighted a safety signal regarding risk of pancreatitis. Like CARMELINA, the albiglutide study (Harmony Outcome) had a very high CV event rate. Despite being a short duration study, albiglutide showed strong superiority for reduction in the major adverse CV events (MACE) composite in people with extant cardiovascular disease (CVD), in line with the earlier studies on the GLP-1 receptor agonists (GLP-1RAs) liraglutide and semaglutide. Positive effects can be detected for all these medications from before 12 months and continue for the whole study duration. No new safety issues for albiglutide are identified and the lack of a pancreatitis or a pancreatic cancer signal for this class is now clear. For the sodium-glucose cotransporter-2 (SGLT2) inhibitor class, the DECLARE-TIMI 58 study (of dapagliflozin) clearly indicates strong protection for heart failure in those with CVD, and probably in those with no prior CVD. There is also strong protection against renal decline with dapagliflozin, with similar risk estimates in DECLARE as previously reported for empagliflozin and canagliflozin. However, findings for MACE outcomes with dapagliflozin are not concordant with the empagliflozin and canagliflozin studies, and are not convincingly superior across class and for the longer term. Care is required when prescribing the SGLT2 inhibitor class of medications to people with foot vascular issues or prior amputation, and to insulin users in regard of ketoacidosis. In summary, taking into account the findings from these new studies, it is suggested that a GLP-1RA should be offered to all people with CVD and type 2 diabetes, and SGLT2 inhibitors should be prescribed for those at high risk of heart failure or with progressive decline in eGFR. DPP4 inhibitors are a safe choice within the glucose-lowering stepped algorithm.
引用
- Home P. Cardiovascular outcome trials of glucose-lowering medications: an update. Diabetologia. 2019. PMID: 30607467. doi:10.1007/s00125-018-4801-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。